Professor; Head of Division
German Center for Neurodegenerative Diseases (DZNE), and Center of Neurology, University Tübingen
Matthis Synofzik
- 2026
- Attendee
- 2026
- Speaker
- Circle
What if a drug could be made for one person – possibly the only one on Earth with their disease? Matthis Synofzik makes it happen. As Professor and Head of Translational Genomics at the University of Tübingen’s Hertie Institute and DZNE Tübingen, he programmes antisense oligonucleotides (ASOs) as keys cut for a single genetic lock. His team delivered Europe’s first individualised ASO therapy for a brain disease, treating a five-year-old boy. Now, like a locksmith’s workshop, his platform of 22 programmes cuts key after key – turning ‘too rare to treat’ into ‘next in line’